Pharming Group (DE:PHGN)
FRANKFURT:PHGN
Holding DE:PHGN?
Track your performance easily

Pharming Group (PHGN) Income Statement

2 Followers

Pharming Group Income Statement

Last quarter (Q4 2023), Pharming Group's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q4, Pharming Group's net income was $―. See Pharming Group’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 104.38M$ 245.32M$ 205.62M$ 198.87M$ 212.17M$ 169.02M
Cost of Revenue
$ 6.41M$ 25.21M$ -17.56M$ -21.14M$ -23.54M$ 21.36M
Gross Profit
$ 97.97M$ 220.10M$ 188.06M$ 177.73M$ 188.63M$ 147.67M
Operating Expense
$ 72.39M$ 244.18M$ 184.30M$ 166.80M$ 114.20M$ 86.76M
Operating Income
$ 25.59M$ -24.07M$ 3.76M$ 10.93M$ 74.44M$ 60.91M
Net Non Operating Interest Income Expense
$ 3.47M$ -2.44M$ -978.00K$ 8.71M$ -32.59M$ -10.91M
Other Income Expense
$ -219.00K$ -17.47M$ -12.26M$ -3.41M$ -2.23M$ -3.32M
Pretax Income
$ 28.84M$ -12.01M$ 14.99M$ 23.08M$ 44.09M$ 46.68M
Tax Provision
$ 3.99M$ -1.46M$ 1.31M$ 7.08M$ 6.35M$ 10.48M
Earnings From Equity Interest Net Of Tax
-$ -289.00K$ -1.08M$ 694.00K$ 362.00K-
Net Income Common Stockholders
$ 24.84M$ -10.55M$ 13.72M$ 15.96M$ 37.73M$ 36.20M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 78.80M$ 269.39M$ 166.74M$ 145.66M$ 90.66M$ 108.11M
Net Income From Continuing And Discontinued Operation
$ 24.84M$ -10.55M$ 13.72M$ 15.96M$ 37.73M$ 36.20M
Normalized Income
$ 24.84M----$ 38.95M
Interest Expense
$ 2.60M----$ 11.92M
EBIT
$ 31.43M-$ 11.04M$ 18.63M$ 41.95M$ 58.60M
EBITDA
$ 35.46M-$ 24.22M$ 38.24M$ 50.27M$ 63.77M
Currency in USD

Pharming Group Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis